25 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
balance between management and independent leadership participation in our board of directors proceedings.
Board Determination of Independence
Rule 5605 … committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act, and compensation committee members must also
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
to response3: 1.2 months Median duration of response: 10.8 months Overall survival for complete responders: 18 months 72% Transfusion independence 2023
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
25 May 23
Regulation FD Disclosure
5:10pm
in Transfusion Hematologic CR/CRi CR/CRi 1 low-blast independence response Rate Rate subset Median time to response: 1.2 months including one marrow CR Median
8-K
EX-99.1
c0arn xazx
26 May 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
bet60 eil8m
25 Feb 21
Regulation FD Disclosure
7:01am
8-K
EX-99.1
24htvna6vul 48g
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.2
bpf7iu yt8yd
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.1
r3ebg02l2zzjhaf
13 Jan 20
Regulation FD Disclosure
6:11am
8-K
EX-99.1
wxp2v0d3qq81ocdmhjw
2 Dec 19
Regulation FD Disclosure
7:03am
8-K
EX-99.1
13ncp0 24
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am